---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Expected outcomes of therapy"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Expected outcomes of therapy. Topics: NATIVE: histologic response at week 24, full analysis population with multiple imputation; Fibrosis regression as a predictor of reduced liver-related events (NATIVE discussion); Mortality by fibrosis stage in biopsy-proven NAFLD (meta-analysis of 14 studies); Untreated progression and regression times per fibrosis stage (meta-analysis of 54 studies); 3 further topics. 8 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description/expected-outcomes-of-therapy"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Expected outcomes of therapy

<a id="heading-2.2.2.7"></a>

## 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

### Summary

In the NATIVE trial at week 24, in the full analysis population with missing data handled by multiple imputation, a decrease of at least 2 points in the SAF-A score without worsening of fibrosis (the primary end point) occurred in 55% of participants receiving lanifibranor 1200 mg (significant) and 48% receiving 800 mg (not significant), compared with 33% receiving placebo; resolution of NASH without worsening of fibrosis occurred in 49%, 39%, and 22%. The company topline release reported the primary end point in the ITT population as 49% (1200 mg, P=0.004), 41% (800 mg, P=0.061), and 27% (placebo). The trial publication states that fibrosis is the primary predictor of complications and death in NASH and that regression of fibrosis is associated with decreased risk of liver-related events.

Evidence linking fibrosis stage to outcomes comes from pooled cohort studies and models. Across cohort studies of biopsy-proven NAFLD, stage 3 to 4 fibrosis carried higher all-cause (HR 3.32) and liver-related mortality (HR 10.40) than stage 0 to 2. The estimated time to progress by one stage was 13.3 years from F2 and 22.2 years from F3, and the time to regress by one stage was 12.5 years from F3 and 20.4 years from F2. A US model estimated that a hypothetical therapy halting fibrosis progression in MASLD would reduce cases of decompensated cirrhosis by 11-39%, hepatocellular carcinoma by 10-34%, and liver-related deaths by 8-31%. The AASLD resmetirom update states that stabilization of fibrosis may portend important long-term benefits. The EASL guideline states that agents receiving accelerated approval for MASH must demonstrate beneficial effects on clinical outcomes (mortality, decompensation, liver transplantation, and hepatocellular carcinoma).

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205); [Inventiva NATIVE topline results release (2020)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-NATIVE-top-line-results-EN-15062020.pdf); [Ng et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10792524/); [Le et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9898457/); [Wallace et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39832655/); [Chen et al. (2025)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001112~resmetirom-therapy-for-metabolic-dysfunction-associated); [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.2.7-2"></a>

### NATIVE: histologic response at week 24, full analysis population with multiple imputation

> “In the full analysis population in which missing data were handled with multiple imputation, the percentage of patients who had a decrease of at least 2 points in the SAF-A score without worsening of fibrosis (the primary end point) was significantly higher among those who received the 1200-mg dose (55%), but not among those who received the 800-mg dose (48%), of lanifibranor than among those who received placebo (33%)”
> “Resolution of NASH without worsening of fibrosis at week 24 from baseline was observed in 49% of patients who received the 1200-mg dose of lanifibranor, in 39% of patients who received the 800-mg dose, and in 22% of patients who received placebo”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-2.2.2.7-3"></a>

### Fibrosis regression as a predictor of reduced liver-related events (NATIVE discussion)

> “Fibrosis is the primary predictor of medical complications and death in patients with NASH”
> “Regression of fibrosis in NASH is associated with decreased risk of liver-related events”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-2.2.2.7-4"></a>

### Mortality by fibrosis stage in biopsy-proven NAFLD (meta-analysis of 14 studies)

> “Compared with stage 0 fibrosis, all-cause mortality increased with fibrosis stage: stage 2; HR, 1.46 (95% confidence interval [CI], 1.08–1.98), stage 3; HR, 1.96 (95% CI, 1.41–2.72), and stage 4; HR, 3.66 (95% CI, 2.65–5.05). Risk for liver-related mortality increased exponentially as fibrosis stage increased: stage 2; HR, 4.07 (95% CI, 1.44–11.5), stage 3; HR, 7.59 (95% CI, 2.80–20.5), and stage 4; HR, 15.1 (95% CI, 5.27–43.4).”
> “Stage 3 to 4 fibrosis had a higher all-cause (HR, 3.32) and liver-related mortality (HR, 10.40) compared with stage 0 to 2 fibrosis”

Source: [Ng et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10792524/)

<a id="topic-2.2.2.7-5"></a>

### Untreated progression and regression times per fibrosis stage (meta-analysis of 54 studies)

> “Time to progress by 1 fibrosis stage was 9.9, 10.3, 13.3 and 22.2 years for F0, F1, F2, and F3, respectively. Time to regress by 1 stage was 21.3, 12.5, 20.4, and 40.0 years for F4, F3, F2, and F1, respectively.”

Source: [Le et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9898457/)

<a id="topic-2.2.2.7-6"></a>

### Modeled US outcomes of a therapy that halts fibrosis progression in MASLD with moderate-to-advanced fibrosis

> “The scenarios in which a hypothetical therapy halts fibrosis progression resulted in reductions in cases of decompensated cirrhosis (11-39%), hepatocellular carcinoma (10-34%), and liver-related deaths (8-31%), a 9-31% reduction in cumulative DALYs, and $40.5 to $99.1B incremental healthcare costs averted.”
> “Increasing diagnosis and treatment for the MASLD population with moderate-to-advanced fibrosis will prevent advanced liver disease and death and will result in reducing the associated direct healthcare costs.”

Source: [Wallace et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39832655/)

<a id="topic-2.2.2.7-7"></a>

### Fibrosis stabilization as a treatment goal (AASLD October 2024 update)

> “An important consideration is that stabilization of fibrosis may portend important long-term benefits; for persons with advanced fibrosis, apparent lack of fibrosis improvement should not mandate discontinuation of resmetirom therapy.”

Source: [Chen et al. (2025)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001112~resmetirom-therapy-for-metabolic-dysfunction-associated)

<a id="topic-2.2.2.7-8"></a>

### Clinical outcomes not yet demonstrated for therapies approved on histologic endpoints (EASL-EASD-EASO)

> “All pharmacological agents receiving accelerated approval for the treatment of MASH must demonstrate beneficial effects on clinical outcomes (i.e. mortality, decompensation, liver transplantation, HCC) in the extended period of phase III clinical trials and real-world studies.”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
